Reviva Pharmaceuticals Holdings Inc <RVPH.OQ> expected to post a loss of 18 cents a share - Earnings Preview
Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Reviva Pharmaceuticals Holdings Inc is for a loss of 18 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $11.00, above its last closing price of $0.82.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.22 | -0.21 | -0.15 | Beat | 30.2 |
Sep. 30 2024 | -0.27 | -0.25 | -0.25 | Met | -1.6 |
Jun. 30 2024 | -0.29 | -0.29 | -0.26 | Beat | 10.3 |
Mar. 31 2024 | -0.36 | -0.38 | -0.25 | Beat | 33.6 |
Dec. 31 2023 | -0.35 | -0.35 | Met | 0.7 | |
Sep. 30 2023 | -0.43 | -0.37 | -0.44 | Missed | -20.2 |
Jun. 30 2023 | -0.31 | -0.28 | -0.55 | Missed | -99.3 |
Mar. 31 2023 | -0.32 | -0.32 | -0.30 | Beat | 7.7 |
This summary was machine generated May 9 at 15:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
